Supernus Pharmaceuticals' GAAP net income for 9M 2021 was $50.982 million, down 47% from $96.182 million in the previous year. Revenue increased 11.6% to $420.725 million compared to $376.84 million a year earlier.
Supernus Pharmaceuticals' GAAP net income for 9M 2021 was $50.982 million, down 47% from $96.182 million in the previous year. Revenue increased 11.6% to $420.725 million compared to $376.84 million a year earlier. 
ir.supernus.com
English (US) 